The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: a Systematic Review and Bayesian Network Meta-Analysis
Source : https://pubmed.ncbi.nlm.nih.gov/38300476/
Batoclimab had the best efficacy and safety for the treatment of gMG and was ranked first out of the 10 targeted drugs included in this study. Eculizumab was ranked second,...
Batoclimab significantly reduced quantitative myasthenia gravis score in patients with gMG when compared with placebo and was ranked as the most effective drug.
Efficacy of Ravulizumab in Patients With Generalized Myasthenia Gravis by Time From Diagnosis: a Post Hoc Subgroup Analysis of the CHAMPION MG Study
Source : https://pubmed.ncbi.nlm.nih.gov/38380691/
Ravulizumab treatment improved clinical outcomes for patients with AChR+ gMG regardless of time from diagnosis. A numerical trend was observed favoring greater treatment effect with earlier versus later treatment after...
Numerically greater mean treatment effects for improvements in Myasthenia Gravis-Activities of Daily Living and Quantitative Myasthenia Gravis total scores at week 26 were seen in patients starting treatment at ≤2 versus >2 years after diagnosis.
De Novo Onset of Myasthenia Gravis After Kidney Transplantation
Source : https://www.hindawi.com/journals/crit/2024/5473862/
Myasthenia gravis occurring de novo after kidney transplantation is a rare course of severe muscle weakness. A 57-year-old female on treatment with peritoneal dialysis following polycystic kidney disease received a...
In this patient, the profound unexplained weakness that persisted for several weeks after transplant prompted referral to the neurologist, which enabled this rare diagnosis to be made.
The Impact of Myasthenia Gravis Severity on Work and Daily Activities
Source : https://pubmed.ncbi.nlm.nih.gov/38348518/
Patients with MG experience substantial work impairment particularly those with more severe symptoms, highlighting an important way in which patient quality of life is negatively affected. More effective treatment strategies...
Among those currently employed, the mean percentage of work time missed (absenteeism) was 13.3%, percentage impairment of productivity at work was 26.7%, and overall work impairment was 30.0%.
Impact of the COVID-19 Pandemic on People Living With Rare Diseases and Their Families: Results of a National Survey
Source : https://pubmed.ncbi.nlm.nih.gov/38354030/
Self-reported COVID-19 was more frequent than expected and was associated with increased prevalence and severity of RD symptoms and greater use of medications. The pandemic negatively affected access to care...
The racial and ethnic profile of the respondents living with myasthenia gravis was similar to that of the participants of a national registry, but it is possible that the registry also underrepresented minority groups.